A PHASE 2 MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF-04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE

• Register: EUCTR
• Last refreshed on: 19 March 2012
• Main ID: EUCTR2009-012179-82-CZ
• Date of registration: 22/09/2009
• Prospective Registration: Yes
• Primary sponsor: Pfizer Inc., 235 East 42nd Street, New York, NY 10017
• Public title: A PHASE 2 MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF-04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE
• Scientific title: A PHASE 2 MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF-04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE
• Date of first enrolment: 05/01/2010
• Target sample size: 150
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-012179-82
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no

Countries of recruitment

Czech Republic

Key inclusion & exclusion criteria

Inclusion criteria:
1. Age range: 55-85 years of age inclusive
2. Men and women. Women must be of non-childbearing potential defined as either surgically sterile (bilateral tubal ligation, both ovaries removed, or hysterectomy) or post-menopausal for at least 2 years
3. Male subjects must be surgically sterile or must agree to use effective contraception during the period of the trial and for at least 28 days after dosing. The definition of effective contraception is provided in Section 4.4
4. Diagnostic evidence of probable AD consistent with DSM-IV and NINCDS-ADRDA criteria (made by the site Physician at the time of the Screening visit). This evidence must be fully documented in the participant’s file prior to the Baseline Visit
5. MRI (preferred) or CT (if MRI not feasible in the opinion of the Investigator) within the last 12 months consistent with a diagnosis of probable Alzheimer’s disease without any other clinically significant co-morbid pathologies found. If there has been a significant change in clinical status suggestive of stroke or other possible neurological disease with onset between the time of the last MRI or CT and the Screening evaluation, the scan should be repeated if considered appropriate by the Investigator. Subjects with MRI or CT indicating cortical infarct, strategically located subcortical gray matter infarct (eg, hippocampus, thalamus), multiple white matter lacunes or extensive white matter abnormalities should be excluded
6. Subjects with mild to moderate probable Alzheimer’s disease with a Mini Mental State Exam (MMSE) score between 14-26 inclusive at Screening
7. Modified Hachinski Ischemia score =4
8. Subjects must live in the community and have a reliable caregiver or family member who agrees to accompany the patient to all clinic visits, provide information about the patient as required by the Protocol, and ensure compliance with the study medication. The caregiver must be a constant and reliable informant. Subjects with moderate Alzheimer’s disease (MMSE 14-20) must reside with their caregiver. It is preferred that subjects with mild Alzheimer’s disease (MMSE 21-26) also reside with their caregiver but at a minimum the caregiver should have at least 4 hours of direct contact with such subjects 5 days per week
9. Subjects must be able to swallow oral medication in the form of tablets. Tablets are not to be crushed
10. Subjects with controlled hypertension (sitting systolic BP <160 mmHg or a sitting
diastolic BP <95 mmHg) may be included in the study
11. Subjects’ screening 12-lead ECG must demonstrate predominantly normal sinus
rhythm. Minor abnormalities (including sinus bradycardia =50 beats per minute)
documented as clinically insignificant by the Investigator will be allowed. Subjects
with right bundle branch block (complete or partial) and pacemakers may be included
in the study, if considered clinically stable.
12. Subjects must be in reasonably good health in the opinion of the Investigator based on medical history, physical examination, vital signs, 12-lead ECG with no serious or unstable disease within the past 3 months. Subjects with mild, chronic, stable disease (eg, controlled hypertension, osteoarthritis) may be enrolled if deemed medically prudent by the Investigator
13. Subjects and caregivers must provide written Informed Consent and be willing to
comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures
14. Subjects with Type 2 diabetes stabilized by diet and/or oral hyp
Exclusion criteria:
1. Presence of illness apart from AD that could contribute to cognitive dysfunction. Examples include but are not limited to other neurodegenerative disorders (eg, Lewy body dementia, fronto temporal dementia, vascular dementia); psychiatric disorders that meet DSM IV criteria for psychotic disorders, bipolar disorder, alcohol or substance abuse (occurring within the past 10 years); AIDS dementia; tertiary syphilis; or any form of dementia other than Alzheimer’s disease.
2. Subjects with a current vitamin B12 level below either 271 pg/mL or 200 pmol/L, associated with an elevated serum methylmalonic acid (MMA) level.
3. Subjects with thyroid disease unless they are euthyroid and stable on treatment for at least 3 months prior to Screening. Stable treatment must be maintained throughout the study.
4. Subjects felt to have significant suicidal ideation with actual plan and intent or suicidal ideation and for whom it has been determined that it is unsafe to participate in this study. All subjects must be assessed for potential suicidality as described in Section 7.2.4. of the protocol.
5. Subjects with clinically significant cardiovascular disease in the past 6 months prior to screening. Examples of clinically significant cardiovascular disease include:
Myocardial infarction; Coronary Artery Bypass Graft (CABG); Percutaneous Transluminal Coronary Angioplasty (PTCA); Severe or unstable angina; A serious arrhythmia; Clinically significant ECG conduction abnormalities; Moderate to severe heart failure (NYHA Stage III/IV).
6. Subjects with a history of orthostatic blood pressure changes or orthostatic symptoms (such as dizziness, lightheadedness, etc.) which are considered clinically significant by the investigator. Orthostatic hypotension is a decrease of =20 mmHg for systolic blood pressure or =10 mmHg for diastolic blood pressure within 3 minutes of standing from the supine position. Lesser degrees of BP reduction may still be considered clinically significant if the subject becomes symptomatic upon standing, especially in the presence of a significant increase in heart rate (=30 BPM).
7. Subjects experiencing a Transient Ischemic Attack (TIA) in the past 6 months.
8. Subjects with any history of cerebrovascular accident (CVA) or stroke.
9. Subjects with any history of a seizure disorder.
10. Participants with pulmonary disease (eg, interstitial lung disease, moderate or severe or unstable asthma, COPD [emphysema or chronic bronchitis], chronic or acute pneumonitis) or evidence of clinically significant pulmonary symptoms. (Note: If asthma is mild and has not required treatment for 1 year, participant would be allowed).
11. History of cancer within the last 5 years. Treated basal cell or squamous cell carcinoma of the skin is allowed, and stable localized prostate cancer not requiring treatment is allowed.
12. Subjects with evidence or history of diabetes mellitus Type 1.
13. Subjects with a history of acetylcholinesterase inhibitor or memantine use within 84 days (12 weeks) of Baseline.
14. Subjects who are taking or are expected to use prohibited concomitant drugs or restricted concomitant drugs outside the guidelines provided in Appendix 3 and Section 5.5 unless permitted by agreement of sponsor.
15. Treatment with an investigational drug within 3 months or 5 half lives (whichever is longer) preceding Screening.
16. Subjects with a total body weight <90 lb (40.9 kg).
17. Any clinically significant laboratory abnormalities at Scre

Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Alzheimer’s Disease
MedDRA version: 12.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease

Intervention(s)

Product Name: PF-04447943
Product Code: PF-04447943
Pharmaceutical Form: Tablet
Current Sponsor code: PF-04447943
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use

Product Name: PF-04447943
Product Code: PF-04447943
Pharmaceutical Form: Tablet
Current Sponsor code: PF-04447943
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use

Primary Outcome(s)

Main Objective: The primary objective of this Protocol is to assess the efficacy of PF-04447943, relative to placebo, on a performance-based measure of cognition in subjects with mild to moderate AD.

Primary end point(s): Alzheimer’s Disease Assessment Scale-Cognitive Subscale 70 (ADAS-cog)3 at Week 12.

Secondary Objective: The secondary objectives of this study are:
1. To evaluate the effects of PF-04447943 on other clinically relevant measures including behavior, and clinician-rated global change.
2. To evaluate the safety and tolerability of PF-04447943, relative to placebo, in subjects with mild to moderate AD.
3. To evaluate the pharmacokinetics of PF-04447943 in subjects with mild to moderate AD.

Secondary ID(s)

B0401005